Logo image of CORT

CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD

70.9  +0.84 (+1.2%)

Premarket: 70.35 -0.55 (-0.78%)

Fundamental Rating

7

Overall CORT gets a fundamental rating of 7 out of 10. We evaluated CORT against 195 industry peers in the Pharmaceuticals industry. CORT gets an excellent profitability rating and is at the same time showing great financial health properties. CORT is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make CORT a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
CORT had positive earnings in each of the past 5 years.
In the past 5 years CORT always reported a positive cash flow from operatings.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

With an excellent Return On Assets value of 15.83%, CORT belongs to the best of the industry, outperforming 97.44% of the companies in the same industry.
CORT has a better Return On Equity (19.61%) than 92.82% of its industry peers.
The Return On Invested Capital of CORT (13.61%) is better than 90.77% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CORT is above the industry average of 14.87%.
The last Return On Invested Capital (13.61%) for CORT is well below the 3 year average (17.94%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
Industry RankSector Rank
ROA 15.83%
ROE 19.61%
ROIC 13.61%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

With an excellent Profit Margin value of 19.55%, CORT belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
CORT's Profit Margin has declined in the last couple of years.
CORT has a better Operating Margin (16.17%) than 85.13% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 98.43%, CORT belongs to the top of the industry, outperforming 98.46% of the companies in the same industry.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
Industry RankSector Rank
OM 16.17%
PM (TTM) 19.55%
GM 98.43%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CORT is creating value.
Compared to 1 year ago, CORT has more shares outstanding
CORT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 30.24 indicates that CORT is not in any danger for bankruptcy at the moment.
CORT has a better Altman-Z score (30.24) than 94.36% of its industry peers.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 30.24
ROIC/WACC1.38
WACC9.89%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

CORT has a Current Ratio of 3.07. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.07, CORT is in line with its industry, outperforming 53.33% of the companies in the same industry.
A Quick Ratio of 2.96 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Quick ratio of 2.96. This is comparable to the rest of the industry: CORT outperforms 56.92% of its industry peers.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 2.96
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

9

3. Growth

3.1 Past

CORT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.43%, which is quite good.
CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.71% yearly.
The Revenue has grown by 30.93% in the past year. This is a very strong growth!
Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%

3.2 Future

The Earnings Per Share is expected to grow by 56.00% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 31.33% on average over the next years. This is a very strong growth
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y31.33%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

CORT is valuated quite expensively with a Price/Earnings ratio of 61.12.
Compared to the rest of the industry, the Price/Earnings ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 79.49% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.57, CORT is valued quite expensively.
The Price/Forward Earnings ratio is 26.13, which means the current valuation is very expensive for CORT.
Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than 70.77% of the companies in the same industry.
CORT's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.41.
Industry RankSector Rank
PE 61.12
Fwd PE 26.13
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

CORT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CORT is cheaper than 76.92% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than the industry average as 78.97% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 42.44
EV/EBITDA 61.83
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of CORT may justify a higher PE ratio.
CORT's earnings are expected to grow with 70.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.59
PEG (5Y)6.29
EPS Next 2Y47.92%
EPS Next 3Y70.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CORT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (6/16/2025, 8:00:00 PM)

Premarket: 70.35 -0.55 (-0.78%)

70.9

+0.84 (+1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-28 2025-07-28/amc
Inst Owners79.51%
Inst Owner Change-1.54%
Ins Owners6.55%
Ins Owner Change0.43%
Market Cap7.52B
Analysts82
Price Target141.01 (98.89%)
Short Float %13.47%
Short Ratio8.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.62%
Min EPS beat(2)-40.2%
Max EPS beat(2)16.96%
EPS beat(4)3
Avg EPS beat(4)13.93%
Min EPS beat(4)-40.2%
Max EPS beat(4)42.54%
EPS beat(8)7
Avg EPS beat(8)20.33%
EPS beat(12)9
Avg EPS beat(12)10.46%
EPS beat(16)12
Avg EPS beat(16)11.02%
Revenue beat(2)0
Avg Revenue beat(2)-11.81%
Min Revenue beat(2)-13.38%
Max Revenue beat(2)-10.25%
Revenue beat(4)2
Avg Revenue beat(4)-4.03%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)-0.63%
Revenue beat(12)7
Avg Revenue beat(12)-1.42%
Revenue beat(16)8
Avg Revenue beat(16)-1.72%
PT rev (1m)-0.9%
PT rev (3m)38.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-60.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-34.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.7%
Valuation
Industry RankSector Rank
PE 61.12
Fwd PE 26.13
P/S 10.97
P/FCF 42.44
P/OCF 41.9
P/B 11
P/tB 11
EV/EBITDA 61.83
EPS(TTM)1.16
EY1.64%
EPS(NY)2.71
Fwd EY3.83%
FCF(TTM)1.67
FCFY2.36%
OCF(TTM)1.69
OCFY2.39%
SpS6.46
BVpS6.44
TBVpS6.44
PEG (NY)4.59
PEG (5Y)6.29
Profitability
Industry RankSector Rank
ROA 15.83%
ROE 19.61%
ROCE 15.76%
ROIC 13.61%
ROICexc 25.27%
ROICexgc 25.27%
OM 16.17%
PM (TTM) 19.55%
GM 98.43%
FCFM 25.85%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 159.44%
Profit Quality 132.22%
Current Ratio 3.07
Quick Ratio 2.96
Altman-Z 30.24
F-Score6
WACC9.89%
ROIC/WACC1.38
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y31.33%
EBIT growth 1Y-9.1%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year20.41%
EBIT Next 3Y47.8%
EBIT Next 5Y19.15%
FCF growth 1Y60.04%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y61.51%
OCF growth 3Y5.66%
OCF growth 5Y7.79%